A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

You may be eligible if

• Patients:
• with schizophrenia being treated with olanzapine, risperidone, or quetiapine for at least 3 months
• with diagnosis of metabolic syndrome
• not treated for 1 of the parameters of metabolic syndrome